Cytokinetics | CYTK - Cash And Equivalent


Cytokinetics reported $255.27M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Arca Biopharma USD 49.52M 2.58M Mar/2026
Bayer EUR 5.73B 943M Mar/2026
Biogen USD 1.28B 2.1B Jun/2026
Brainstorm Cell Therapeutics USD 15K 14K Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Capricor Therapeutics USD 105.42M 182.42M Mar/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Exelixis USD 226.15M 256.34M Mar/2026
Geron USD 62.64M 6.25M Jun/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026